Enhanced Composition for Preventing or Treating Obesity or Lipid-Related Metabolic Disorders

The present inventive concept discloses an improved composition and system for preventing or treating obesity or lipid-related metabolic disorders, addressing the limitations of existing treatments by enhancing bioavailability, efficacy, and personalized treatment options.

The original patent application relates to a functional composition for the prevention, amelioration, or treatment of obesity or lipid-related metabolic disease. However, the existing composition has limitations in terms of bioavailability, efficacy, and potential adverse effects. The new inventive concept addresses these limitations by introducing a steroid sulfatase inhibitor in combination with a nutrient supplement, a lipase inhibitor, or an antioxidant, thereby enhancing the treatment outcomes and reducing the risk of adverse effects.

The inventive concept comprises a system and method for preventing or treating obesity or lipid-related metabolic disorders, utilizing a steroid sulfatase inhibitor in combination with a nutrient supplement to enhance bioavailability, a lipase inhibitor to increase efficacy, or an antioxidant to reduce the risk of adverse effects. The system may further include a diagnostic tool for determining the optimal dosage of the inhibitor based on an individual's genetic profile, enabling personalized treatment options. The pharmaceutical composition is formulated for oral administration, providing a convenient and effective treatment option.

The new inventive concept introduces a novel combination of a steroid sulfatase inhibitor with a nutrient supplement, a lipase inhibitor, or an antioxidant, which is not obvious from the original patent. The addition of these components enhances the bioavailability, efficacy, and safety of the treatment, providing a significant improvement over the existing composition.

Alternative embodiments of the inventive concept may include different formulations of the pharmaceutical composition, such as topical or injectable forms, or varying ratios of the steroid sulfatase inhibitor to the nutrient supplement or lipase inhibitor. Additionally, the diagnostic tool may be replaced with other methods for determining the optimal dosage, such as biomarkers or genetic testing.

The inventive concept has significant commercial potential in the treatment of obesity or lipid-related metabolic disorders, with a growing market demand for effective and safe treatment options. The enhanced composition and system may be marketed to pharmaceutical companies, healthcare providers, and patients, offering a competitive advantage in the treatment of these diseases.